Skip to main content

Table 6 Effect of tolvaptan at baseline and during inhibition of the nitric oxide system on pulse wave velocity (PWV), augmentation index (AI), central diastolic and systolic blood pressure (CBDP and CSBP) in a randomized, placebo-controlled, double-blind, crossover study of 19 healthy subjects

From: Effect of vasopressin antagonism on renal handling of sodium and water and central and brachial blood pressure during inhibition of the nitric oxide system in healthy subjects

Periods Baseline L-NMMA
PWV(m/s)
Placebo 5.3 ± 0.7 5.5 ± 0.5
Tolvaptan 5.3 ± 0.6 5.6 ± 0.7*
p (paired t-test, between) 0.652 0.929
AI
Placebo 0.0 ± 18.7 3.7 ± 18.7
Tolvaptan 1.2 ± 18.3 7.2 ± 17.5*
p (paired t-test, between) 0.646 0.064
CSBP
Placebo 100 ± 7 105 ± 4
Tolvaptan 100 ± 4 107 ± 7*
p (paired t-test, between) 0.871 0.351
CDBP
Placebo 66 ± 12 70 ± 8*
Tolvaptan 64 ± 5 68 ± 8*
p (Wilcoxon signed rank test, between) 0.440 0.622
  1. Data are shown as mean with ± SD or medians with ± interquartile range. Paired t-test or Wilcoxon signed rank test was used for comparison within (*) treatment group at baseline vs during infusion period 90–150 min, and at baseline vs post infusion period 150 – 210 min. *p < 0.05.